This inventor holds 7 USPTO granted patents and 1 published patent application. Top assignee: King Saud University. Active years: 2018-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2019
Title: Abd El-Galil E Amr: Innovator in Pharmaceutical Chemistry
Introduction
Abd El-Galil E Amr is a prominent inventor based in Riyadh, Saudi Arabia. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on various chemical compounds. With a total of 7 patents to his name, his research focuses on developing new derivatives that have potential therapeutic applications.
Latest Patents
One of his latest patents involves the development of ursolic acid derivatives. These derivatives exhibit potent selective calcium channel blocker activities, which may be beneficial in treating diseases or conditions that require calcium channel regulation. Another notable patent is related to sulfonylurea derivatives of oleanolic acid. These compounds replace the 5-chloro-2-methoxybenzoic acid moiety found in glibenclamide with oleanolic acid. The resulting triterpenoidal sulfonylurea derivatives have shown promising oral hypoglycemic activity in vivo, proving to be more potent than either glibenclamide or oleanolic acid.
Career Highlights
Abd El-Galil E Amr is affiliated with King Saud University, where he conducts his research and development activities. His work has garnered attention in the scientific community, contributing to advancements in drug development and therapeutic solutions.
Collaborations
He has collaborated with notable colleagues, including Mohamed Abdulrahman Al-Omar and Ahmed Mohamed Naglah. These partnerships have further enriched his research endeavors and expanded the impact of his inventions.
Conclusion
Abd El-Galil E Amr stands out as an influential inventor in the realm of pharmaceutical chemistry. His innovative patents and collaborative efforts continue to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile